Sun to acquire DUSA Pharmaceuticals
The US$230m deal will allow Sun to enter the dermatology market
Indian drugmaker Sun Pharmaceutical Industries is to purchase DUSA Pharmaceuticals, a US-based company focused on dermatology treatments, for US$230m.
DUSA’s Levulan (aminolevulinic acid HCl) is approved by the FDA for treating non-hyperkeratotic actinic keratoses of the face or scalp.
The FDA has also approved DUSA’s BLU-U treatment for moderate inflammatory acne vulgaris and general dermatological conditions.
The boards of directors of both companies have unanimously approved the deal.
Dilip Shanghvi, managing director of Sun Pharmaceutical Industries, said: ‘DUSA’s business brings us an entry into dermatological treatment devices, where we see good growth opportunities.’
Robert Doman, president and CEO of DUSA, added: ‘We are confident that Sun Pharma will build upon the solid foundation our organisation has established in the US dermatology market to further expand access to Levulan for patients with actinic kerotoses.’
